Industry News

Fortress Biotech, Inc. company, launched Targadox™ 50 mg film coated tablets indicated as adjunctive therapy for the treatment of severe acne."/>
Journey Medical Corporation Launches Targadox™ Oral Immediate-Release Tablet for Treatment of Severe Acne
Allergan plc, a leading global pharmaceutical company, today announced that it has two presentations including a late breaking abstract that will be presented for the first time at the 72 nd American Society of Reproductive Medicine Scientific Congress and Expo in Salt Lake City, Utah, October 15-19.. The scheduled times of the presentations and room locations at the Salt Palace Convention Center are as follows:. "First US-Based Phase 3 Study of..."/>
Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City
Eiger BioPharmaceuticals, Inc., focused on the development and commercialization of therapies for rare diseases, announced today that the European Medicines Agency has granted orphan designation to exendin 9-39 for the treatment of non-insulinoma pancreatogenous hypoglycemia syndrome. NIPHS describes a spectrum of acquired metabolic disorders characterized by inappropriately high insulin levels and low blood glucose..."/>
Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)
Mast Therapeutics, Inc. today announced that its wholly-owned subsidiary, Aires Pharmaceuticals, Inc., has entered into a collaborative agreement with Philips Respironics, Inc., the sleep and respiratory care business of Royal Philips related to the supply of Philips' I-neb ® Adaptive Aersol Delivery devices and related consumables for the nebulized delivery of the Company's lead product candidate, AIR001, a sodium nitrite solution for..."/>
Mast Therapeutics Announces Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001
Lipocine Inc., a specialty pharmaceutical company, today announced the completion of a Post Action meeting with the U.S. Food and Drug Administration regarding its New Drug Application for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism. The purpose of the meeting was to review the..."/>
Lipocine Completes Post Action Meeting With FDA for LPCN 1021 New Drug Application
Dextera Surgical Inc., manufacturer of the smallest-profile and most maneuverable articulating surgical stapler platform on the market for minimally invasive surgery, today announced the company has entered into a marketing and distribution agreement with B. Braun Surgical S.A. to bring Dextera’ s MicroCutter 5/ 80 surgical stapler to surgeons in Spain. B. Braun Surgical S.A. is the distribution arm of the B. Braun Aesculap Group headquartered in..."/>
Dextera Surgical Signs Agreement with B. Braun Surgical S.A. for MicroCutter Distribution in Spain
ConforMIS, Inc., a medical technology company that develops, manufactures and sells joint replacement implants that are customized to fit each patient's unique anatomy, today announced that The Journal of Arthroplasty has accepted for printed publication, and published online, the results of an in vivo clinical study comparing the motion patterns of patients with a ConforMIS iTotal ® CR implant versus patients with a traditional off-the-shelf..."/>
ConforMIS Announces Publication of Clinical Study Demonstrating iTotal CR Customized Implants Better Approximate Normal Knee Motion When Compared to a Leading Off-the-Shelf Total Knee Implant
Allergan plc, a leading global pharmaceutical company, and Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company, today announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Allergan's pending acquisition of Vitae. The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending..."/>
Allergan and Vitae Pharmaceuticals Announce Expiration of HSR Waiting Period for Allergan's Proposed Acquisition of Vitae
Teladoc, Inc., the first and largest telehealth platform in the United States, announced that Alan Roga, MD, FACEP, Teladoc senior vice president and general manager, provider market, will participate in the J.P. Morgan Healthcare Banking Group’ s 4th Annual Healthcare Advisory Council."/>
Teladoc Senior Vice President Dr. Alan Roga to Address Hospital and Health System Chief Financial Officers at J.P. Morgan Healthcare Advisory Council
Synergy Pharmaceuticals Inc. today presented new long-term safety data of plecanatide, its investigational, orally-administered compound currently being evaluated by the U.S. Food and Drug Administration for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. These data, which were presented at the American College of Gastroenterology annual scientific meeting, showed that plecanatide was associated with low..."/>
Synergy Pharmaceuticals Presents Long-Term Data for Plecanatide in Chronic Idiopathic Constipation at the American College of Gastroenterology (ACG) Annual Scientific Meeting
PerkinElmer Elects Samuel Chapin to Board of Directors

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology1,027 Articles
Consumer Discretionary815 Articles
Financials749 Articles
Health Care639 Articles
Industrials579 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at